Tissue Regenix (TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for the repair of soft tissue (dCELL) and bone (BioRinse). Following its acquisition of CellRight, management embarked on a revised commercial strategy to increase sales momentum, and it has recently secured expanded Group Purchasing Organisation (GPO) coverage in the US for DermaPure. TRX should benefit in 2019 from the US and European commercial agreements made with leading orthopaedic company, Arthrex, in 2018.
10 Apr 2019
Expanded GPO coverage secured
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Expanded GPO coverage secured
Tissue Regenix Group plc (TRX:LON) | 61.5 0 0.0% | Mkt Cap: 43.4m
- Published:
10 Apr 2019 -
Author:
Martin Hall -
Pages:
5
Tissue Regenix (TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for the repair of soft tissue (dCELL) and bone (BioRinse). Following its acquisition of CellRight, management embarked on a revised commercial strategy to increase sales momentum, and it has recently secured expanded Group Purchasing Organisation (GPO) coverage in the US for DermaPure. TRX should benefit in 2019 from the US and European commercial agreements made with leading orthopaedic company, Arthrex, in 2018.